Pacific Biosciences of California (PACB) - Total Liabilities
Based on the latest financial reports, Pacific Biosciences of California (PACB) has total liabilities worth $780.00 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Pacific Biosciences of California growing its equity to track the company's year-over-year net asset growth rate.
Pacific Biosciences of California - Total Liabilities Trend (2008–2025)
This chart illustrates how Pacific Biosciences of California's total liabilities have evolved over time, based on quarterly financial data. See PACB free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Pacific Biosciences of California Competitors by Total Liabilities
The table below lists competitors of Pacific Biosciences of California ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SUNSEA Telecommunications Co Ltd
SHE:002313
|
China | CN¥2.99 Billion |
|
Sports Gear Co. Ltd
TW:6768
|
Taiwan | NT$8.58 Billion |
|
Hu Lane Associate
TWO:6279
|
Taiwan | NT$6.70 Billion |
|
Ratchthani Leasing Public Company Limited
BK:THANI
|
Thailand | ฿26.90 Billion |
|
Medistim ASA
OL:MEDI
|
Norway | Nkr151.23 Million |
|
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
|
USA | $87.84K |
|
Wilson Bayly Holmes Ovcon Ltd
JSE:WBO
|
South Africa | ZAC9.51 Billion |
|
Delek Automotive Systems Ltd
TA:DLEA
|
Israel | ILA8.22 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Pacific Biosciences of California's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Pacific Biosciences of California market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 329.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pacific Biosciences of California's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pacific Biosciences of California (2008–2025)
The table below shows the annual total liabilities of Pacific Biosciences of California from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $778.73 Million | +3.30% |
| 2024-12-31 | $753.85 Million | -27.84% |
| 2023-12-31 | $1.04 Billion | -13.24% |
| 2022-12-31 | $1.20 Billion | -0.97% |
| 2021-12-31 | $1.22 Billion | +1449.24% |
| 2020-12-31 | $78.49 Million | -15.66% |
| 2019-12-31 | $93.07 Million | +65.56% |
| 2018-12-31 | $56.21 Million | -3.05% |
| 2017-12-31 | $57.98 Million | +8.95% |
| 2016-12-31 | $53.22 Million | -7.56% |
| 2015-12-31 | $57.57 Million | -17.26% |
| 2014-12-31 | $69.57 Million | +3.83% |
| 2013-12-31 | $67.00 Million | +230.06% |
| 2012-12-31 | $20.30 Million | -24.40% |
| 2011-12-31 | $26.85 Million | +3.76% |
| 2010-12-31 | $25.88 Million | -90.70% |
| 2009-12-31 | $278.22 Million | +34.73% |
| 2008-12-31 | $206.50 Million | -- |
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stran… Read more